News
-
Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease
Milan, ITALY – May 18, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today ...
-
Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease 7 Years Before Symptoms Occur
Milan, ITALY – May 13, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today ...
-
New Scientific Publications Show Diadem’s Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer’s Disease Years Before Symptoms Occur
Milan, ITALY – February 01, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the publication...
-
Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer’s Disease International Conference
Milan, ITALY – December 11, 2020
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it hosted a Symposium on its prognostic biomarker...
-
Diadem Names Dr. Tamas Bartfai Chair of Its Medical Advisory Board
Milan, ITALY – December 1, 2020
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that noted neuroscientist and Alzheimer’s disease...
-
Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize
Milan, ITALY – November 16, 2020
pool of 600 applicants. The companies were analyzed by experts representing relevant public, private, financial, technological and specialist...
-
Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
Milan, ITALY – October 19, 2020
Diadem srl, a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that Paul Kinnon has been named...
Italiano | English